The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients

European Psychiatry

Volumn 28, Issue 6, 2013, Pages 340-343

  Fischel, T ^a,b   Krivoy, A ^a,b   Kotlarov, M ^b   Zemishlany, Z ^a,b   Loebstein, O ^a,b   Jacoby, H ^a   Weizman, A ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Affective flattening; Antipsychotic drugs; Schizophrenia; Subjective attitude; Subjective experience

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AFFECT; ANHEDONIA; ARTICLE; CORRELATION ANALYSIS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERSONAL EXPERIENCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUESTIONNAIRE; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SOCIAL BEHAVIOR; WEIGHT GAIN;

AFFECTIVE FLATTENING; ANTIPSYCHOTIC DRUGS; SCHIZOPHRENIA; SUBJECTIVE ATTITUDE; SUBJECTIVE EXPERIENCE;

ADULT; AFFECT; ANTIPSYCHOTIC AGENTS; ATTITUDE; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN;

EID: 84880748033     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2012.06.005     Document Type: Article

References (19)

1. Awad A.G., Hogan T.P. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl 1994, 380:27-32.
2. Awad A.G., Voruganti L.N., Heslegrave R.J., Hogan T.P. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996, 11(Suppl. 2):55-59.
3. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36(1):71-93.
4. Gaebel W., Riesbeck M., von W.M., Burns T., Derks E.M., Kahn R.S., et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol 2010, 20(5):310-316.
5. Hellewell J.S. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002, 16(7):457-471.
6. Hofer A., Kemmler G., Eder U., Honeder M., Hummer M., Fleischhacker W.W. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002, 63(1):49-53.
7. Hofer A., Rettenbacher M.A., Edlinger M., Kemmler G., Widschwendter C.G., Fleischhacker W.W. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand 2007, 116(5):354-361.
8. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13(1):177-183.
9. Hogan T.P., Awad A.G., Eastwood M.R. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 1985, 30(4):246-248.
10. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63(10):1079-1087.
11. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
12. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63(10):892-909.
13. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223.
14. Moncrieff J., Cohen D., Mason J.P. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009, 120(2):102-111.
15. Naber D. Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiol Psichiatr Soc 2008, 17(3):174-176.
16. Novick D., Haro J.M., Suarez D., Perez V., Dittmann R.W., Haddad P.M. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010, 176(2-3):109-113.
17. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010, 16(5):306-324.
18. Wolters H.A., Knegtering R., Wiersma D., van den Bosch R.J. Evaluation of the subjects' response to antipsychotics questionnaire. Int Clin Psychopharmacol 2006, 21(1):63-69.
19. Wolters H.A., Knegtering H., van den Bosch R.J., Wiersma D. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophr Res 2009, 112(1-3):114-118.